SCHEMBL29759653

SCHEMBL29759653

Cc1ncc(NC(=O)OC(C)(C)C)cc1NC(=O)c1cnn2cc(-c3cnn(C)c3)sc12

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 3/20 0.42
▸ KIT P10721 2/20 0.42
▸ GSK3B P49841 1/20 0.41
▸ DYRK1A Q13627 1/20 0.41
▸ PDGFRA P16234 2/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.38
▸ IRAK4 Q9NWZ3 1/20 0.34
▸ IKBKE Q14164 1/20 0.33
▸ TBK1 Q9UHD2 1/20 0.33
▸ RET P07949 5/20 0.33
▸ DGAT1 O75907 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ RORC P51449 1/20 0.32
▸ MAPKAPK2 P49137 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24576975 1.00 CSF1R (0.42) CSF1RKITGSK3BDYRK1APDGFRA
SCHEMBL24577724 0.91 CSF1R (0.42) CSF1RKITDYRK1APDGFRACHRM1
SCHEMBL24577084 0.90 IKBKE (0.37) CSF1RKITGSK3BDYRK1APDGFRA
SCHEMBL24577335 0.89 IKBKE (0.41) CSF1RKITGSK3BDYRK1APDGFRA
SCHEMBL27185302 0.89 KIT (0.44) CSF1RKITDYRK1APDGFRACHRM1
SCHEMBL29759686 0.88 KIT (0.33) CSF1RKITGSK3BDYRK1APDGFRA
SCHEMBL24579033 0.88 KIT (0.33) CSF1RKITGSK3BDYRK1APDGFRA
SCHEMBL24579081 0.88 KIT (0.43) CSF1RKITDYRK1APDGFRACHRM1
SCHEMBL24577348 0.88 CSF1R (0.34) CSF1RKITGSK3BDYRK1APDGFRA
SCHEMBL24579009 0.88 RAF1 (0.34) CSF1RKITGSK3BDYRK1AIRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2024-04-04 — — US disclosed
WO-2023247596-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2023-12-28 — — WO disclosed
EP-4267585-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS Actelion Pharmaceuticals Ltd (CH) 2023-11-01 — — EP disclosed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS PDGFRA, PDGFRB, ABL1 CSF1R 173/4885KIT 6/4885GSK3B 1914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback